KR20220079917A - 혈관신생 안 질환의 치료 또는 예방을 위한 칼레티쿨린 - Google Patents

혈관신생 안 질환의 치료 또는 예방을 위한 칼레티쿨린 Download PDF

Info

Publication number
KR20220079917A
KR20220079917A KR1020227015264A KR20227015264A KR20220079917A KR 20220079917 A KR20220079917 A KR 20220079917A KR 1020227015264 A KR1020227015264 A KR 1020227015264A KR 20227015264 A KR20227015264 A KR 20227015264A KR 20220079917 A KR20220079917 A KR 20220079917A
Authority
KR
South Korea
Prior art keywords
calreticulin
pharmaceutical composition
eye
crt
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227015264A
Other languages
English (en)
Korean (ko)
Inventor
리만타스 슬리빈스카스
에발다스 치플리스
Original Assignee
유에이비 발티마스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유에이비 발티마스 filed Critical 유에이비 발티마스
Publication of KR20220079917A publication Critical patent/KR20220079917A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1738—Calcium binding proteins, e.g. calmodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020227015264A 2019-10-08 2020-10-07 혈관신생 안 질환의 치료 또는 예방을 위한 칼레티쿨린 Ceased KR20220079917A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1914516.8 2019-10-08
GB201914516A GB201914516D0 (en) 2019-10-08 2019-10-08 Treatment of eye disease
PCT/EP2020/078173 WO2021069523A1 (en) 2019-10-08 2020-10-07 Calreticulin for treating or preventing an angiogenic eye disease

Publications (1)

Publication Number Publication Date
KR20220079917A true KR20220079917A (ko) 2022-06-14

Family

ID=68541456

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227015264A Ceased KR20220079917A (ko) 2019-10-08 2020-10-07 혈관신생 안 질환의 치료 또는 예방을 위한 칼레티쿨린

Country Status (6)

Country Link
US (1) US20220370554A1 (enExample)
EP (1) EP4041280A1 (enExample)
JP (1) JP2023500033A (enExample)
KR (1) KR20220079917A (enExample)
GB (1) GB201914516D0 (enExample)
WO (1) WO2021069523A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114699506A (zh) * 2021-12-30 2022-07-05 北京百华百汇生物科技有限公司 重组钙网蛋白在生发、育发、保护毛发或防脱发中的用途和相关产品

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020577A1 (en) 1998-10-06 2000-04-13 The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Huuman Services, The National Institutes Of Health Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth
US6867180B1 (en) 1998-10-06 2005-03-15 The United States Of America As Represented By The Department Of Health And Human Services Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth
WO2011160082A2 (en) * 2010-06-17 2011-12-22 New York University Therapeutic and cosmetic uses and applications of calreticulin
TWI445543B (zh) 2012-05-03 2014-07-21 Univ Nat Sun Yat Sen 一種用以治療眼部脈絡膜血管新生之醫藥組合物
WO2014011723A1 (en) 2012-07-12 2014-01-16 Uab Baltymas Generation of native recombinant secreted human endoplasmic reticulum chaperones by using their native signal sequences in yeast expression systems
GB201401453D0 (en) * 2014-01-28 2014-03-12 Univ Birmingham Transmucosal and transepithelial drug delivery system

Also Published As

Publication number Publication date
US20220370554A1 (en) 2022-11-24
WO2021069523A1 (en) 2021-04-15
GB201914516D0 (en) 2019-11-20
EP4041280A1 (en) 2022-08-17
JP2023500033A (ja) 2023-01-04

Similar Documents

Publication Publication Date Title
KR102650991B1 (ko) 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물
JP6585720B2 (ja) 眼疾患治療のペプチド及びこれを含む眼疾患治療用組成物
TW202525312A (zh) 腺相關病毒載體醫藥組合物及方法
KR20200029374A (ko) 단백질을 포함하는 액상 조성물
CN103764163A (zh) 纤溶酶原和纤溶酶变体
WO2017101870A1 (zh) 一种预防或治疗糖尿病性视网膜病变的方法
EP2968471A1 (en) Peptides for use in the topical treatment of retinal neurodegenerative disesases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
AU2014346051B2 (en) Use of IL-22 dimers in manufacture of medicaments for treating pancreatitis
CA2955481A1 (en) Collagen iv replacement
TWI677348B (zh) 一種改善心臟病變的方法
TW201927334A (zh) 一種預防或治療骨關節炎的方法及藥物
CA2666843C (en) Treatment of age-related macular degeneration and other diseases of the eye
KR20230141958A (ko) 개선된 치료 지수를 위한 플라스민-내성 펩티드
JP2024059834A (ja) 処置方法および新規構築物
US20220370554A1 (en) Calreticulin for Treating or Preventing an Angiogenic Eye Disease
WO2016064998A1 (en) Promoting epithelial regeneration post tonsillectomy using heparin binding epidermal growth factor like growth factor
ES3048450T3 (en) Components of the plasminogen activation pathway for use in the treatment of hypertension
CN116867511A (zh) 体内半衰期短且体内不稳定的重组微纤溶酶、包含该重组微纤溶酶的药物组合物以及包括施用该重组微纤溶酶的治疗血栓栓塞相关疾病的方法
CN115942951A (zh) Ngf变体，制备，组合物和治疗用途
CA3190013A1 (en) Method and drug for tumor treatment
CN111905103A (zh) 一种治疗肌萎缩侧索硬化的方法和药物
WO2023245543A1 (en) Uses of fgf21 fusion proteins
RU2860337C2 (ru) Офтальмологическая фармацевтическая композиция и ее применение
EP2772498B1 (en) Polypeptides inhibiting neovascularization and uses thereof
Casati et al. Sustained regression of florid diabetic retinopathy in a patient with Donohue syndrome (leprechaunism)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601